Health Catalyst (NASDAQ: HCAT) CPO gets RSU, PRSU grants and tax sell-to-cover

Rhea-AI Filing Summary

Health Catalyst, Inc. Chief People Officer Linda Llewelyn reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 191,500 restricted stock units (RSUs), each representing one share, which will vest in 12 equal quarterly installments beginning on March 1, 2026.

She was also credited with 13,195 performance-based restricted stock units (PRSUs) tied to the company’s performance for the fiscal year ended December 31, 2025. Separately, 4,471 shares were disposed of at $1.7478 per share to cover tax withholding obligations in connection with RSU vesting, under a mandated "sell to cover" election, and not as a discretionary trade. After these transactions, she directly owned 343,487 shares of common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Llewelyn Linda

Role Chief People Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	4,471	$1.7478	$8K
Grant/Award	Common Stock	191,500	$0.00	--
Grant/Award	Common Stock	13,195	$0.00	--

Holdings After Transaction: Common Stock — 343,487 shares (Direct)

Footnotes (1)

1. Represents an award of restricted stock units ("RSUs") granted pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, the RSUs will vest in 12 equal quarterly installments beginning on March 1st 2026. Represents an award of 13,195 performance-based restricted units ("PRSUs") pursuant to the 2019 Plan, based upon the Issuer's satisfaction of certain performance criteria for the fiscal year ended December 31, 2025. Each PRSU represents a contingent right to receive one share of the Issuer's common stock. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Llewelyn Linda

(Last) (First) (Middle)

C/O HEALTH CATALYST, INC.

10897 SOUTH RIVER FRONT PARKWAY, #300

(Street)

SOUTH JORDAN UT 84095

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		A		191,500(1)	A	$0.00	334,763	D
Common Stock	02/25/2026		A		13,195(2)	A	$0.00	347,958	D
Common Stock	02/26/2026		F(3)		4,471	D	$1.7478	343,487	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, the RSUs will vest in 12 equal quarterly installments beginning on March 1st 2026.

2. Represents an award of 13,195 performance-based restricted units ("PRSUs") pursuant to the 2019 Plan, based upon the Issuer's satisfaction of certain performance criteria for the fiscal year ended December 31, 2025. Each PRSU represents a contingent right to receive one share of the Issuer's common stock.

3. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/Benjamin Landry, as Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did HCAT executive Linda Llewelyn receive in this Form 4?

Linda Llewelyn received a grant of 191,500 restricted stock units and 13,195 performance-based restricted stock units. Each unit represents a contingent right to one share of Health Catalyst common stock, subject to future vesting conditions and performance criteria under the 2019 Plan.

How do the 191,500 RSUs granted to HCAT’s Chief People Officer vest?

The 191,500 RSUs vest in 12 equal quarterly installments beginning on March 1, 2026. Vesting is subject to the terms of Health Catalyst’s 2019 Stock Option and Incentive Plan, meaning shares are delivered over time as service-based conditions are met.

What are the 13,195 PRSUs reported for HCAT’s Linda Llewelyn?

The 13,195 PRSUs are performance-based restricted stock units earned under the 2019 Plan. They are based on Health Catalyst’s satisfaction of specified performance criteria for the fiscal year ended December 31, 2025, with each PRSU representing a contingent right to one common share.

Was the 4,471-share disposition by HCAT’s Linda Llewelyn a discretionary sale?

No. The 4,471-share disposition was made solely to cover tax withholding obligations on vesting RSUs. It was mandated by Health Catalyst’s equity plan “sell to cover” election and is described as not representing a discretionary trade by the reporting person.

What price and purpose were disclosed for the 4,471 HCAT shares disposed?

The 4,471 shares of Health Catalyst common stock were disposed of at a price of $1.7478 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations arising from RSU vesting under the company’s equity incentive plans.

How many HCAT shares does Linda Llewelyn own after these transactions?

After the reported equity award grants and the tax-related share disposition, Linda Llewelyn directly owns 343,487 shares of Health Catalyst common stock. This figure reflects her holdings following the most recent transaction disclosed in the Form 4 filing.